US Patent 9,408,840 Landscape and Claim Scope for IBS Treatment Using CoreL-(NHE)2 Compounds

US Patent 9,408,840 claims a composition-linked method for treating irritable bowel syndrome (IBS) in a subject by administering a structurally defined compound featuring a Core scaffold attached to a polyalkylene glycol linker (L) and an NHE moiety repeated twice (n=2). The patent’s practical scope is driven by strict structural limitations: the Core architecture, the linker chemistry (polyalkylene glycol, including PEG), and the NHE substitution pattern (with specific hydrogen and bond relationships) together define a narrow chemical universe. Enforcement and licensing value typically concentrate on: (i) the specific NHE-core-linker architecture, (ii) PEG-length and linker variants that still qualify as “polyalkylene glycol linker,” and (iii) salt forms that map to the patent’s salt definition.

Below is a claim-by-claim scope dissection and a landscape view of what parts of the chemical structure likely control infringement, design-around feasibility, and freedom-to-operate for US IBS drug candidates.

What does US 9,408,840 claim for IBS treatment, and what parts are structurally essential?

Short answer: The patent claims a method of treating IBS by administering a compound where the compound structure is constrained to “Core-L-(NHE)2” (n=2), with NHE and Core defined by nested substituent rules and linker definitions. If any of those structural elements is missing or falls outside the defined categories, the method claim should not read.

Claim 1: the independent claim with the tightest chemical boundaries

Claim 1 is a method claim (not a composition claim). It requires:

A method for treating IBS in a subject needing treatment.
Administration of “a compound, or a pharmaceutically acceptable salt thereof.”
The compound must match the structure (X) described as:
Core-L-(NHE)n (X) with n = 2.
NHE moiety structural constraints:
- NHE is defined as having:
  - R1 is H or —SO2-NR7R8—
  - R2 is selected from:
    - H
    - —NR7(CO)R8
    - —SO2—NR7R8—
    - —NR7R8
  - R3 is hydrogen
  - R7 is hydrogen
  - R8 is a bond linking to L
- L is a polyalkylene glycol linker
Core structural constraints:
Core is defined as a further structure (omitted in your excerpt as a graphical/structured block). The claim text still restricts X’s allowed attachment types and Y’s allowed substituents.
X and Y attachment/substitution options inside Core:
- X is selected from: bond, —O—, —NH—, NHC(═O)—, NHC(═O)NH—, and —NHSO2—
- Y is selected from: bond, optionally substituted C1-6 alkylene, optionally substituted phenyl, pyridinyl, a polyethylene glycol linker, and —(CH2)1-6O(CH2)1-6—.

Why this matters for scope: claim 1 is not a broad functional IBS claim. It is a structure-defined method claim. The patent is likely enforceable only against molecules that retain the “Core-L-(NHE)2” scaffold with NHE substitution patterns meeting the R-group restrictions.

Claim 2: narrows NHE by selecting specific NHE structures

Claim 2 depends on claim 1 and specifies that NHE has one of certain alternative structures (not fully transcribed in your excerpt because the dependent structures appear as images/blocks).

Practical effect: this typically reduces validity risk and clarifies infringement pathways. If accused products use NHE that matches one of the listed NHE embodiments, claim 2 strengthens the case that the asserted compound falls within a specific design variant rather than only the generic “R1/R2/R3/R7/R8” categories.

Claim 3: narrows L to a polyethylene glycol linker

Claim 3 depends on claim 1 and requires:

L is a polyethylene glycol linker (PEG).

Scope impact:

If claim 1 covers “polyalkylene glycol linker,” claim 3 is a subset focused on PEG specifically.
In infringement analysis, if an accused compound uses a different polyalkylene glycol (e.g., polypropylene glycol segments, mixed alkylene glycol polymers) it may still satisfy claim 1 depending on how “polyalkylene glycol” is interpreted, but it would not satisfy claim 3’s PEG-specific limitation.

Claim 4: narrows Core by selecting specific Core embodiments

Claim 4 depends on claim 1 and requires:

Core is selected from the group consisting of: (again, graphical embodiments not fully included in your excerpt).

Scope impact: this makes claim 4 potentially a “preferred infringement anchor.” If the Core in practice is one of the enumerated structures, claim 4 can be directly asserted even if the broader “Core structure” description is ambiguous.

Claims 5 and 6: further limitations on compound selection and salt selection

Your excerpt indicates:

Claim 5: “compound is selected from:” followed by enumerated compound structures (missing in excerpt).
Claim 6: “pharmaceutically acceptable salt is selected from:” followed by enumerated salt forms (missing in excerpt).

Scope impact:

These dependent claims often map to real product forms, e.g., particular counterions and particular named compounds in the specification’s examples.

How should “Core-L-(NHE)2” be treated in infringement analysis for US 9,408,840?

Core-L-(NHE)2 is the center of gravity. A typical infringement map:

1) Does the accused compound have n=2 NHE units?

If the accused structure has only one NHE or three NHE units, it likely falls outside claim 1.
If the accused compound is polymeric or mixture-like, claim construction and proof burdens become central; but the text “n is 2” pushes toward exact stoichiometry in the structure definition.

2) Does NHE satisfy the R1/R2/R3/R7/R8 rules?

Key hard stops:

R3 must be hydrogen
R7 must be hydrogen
R8 must be the bond linking to L
R1 has only two permitted states: H or —SO2-NR7R8—
R2 is constrained to the four listed options (H, —NR7(CO)R8, —SO2—NR7R8—, —NR7R8)

Even small deviations (e.g., R7 not equal to hydrogen, or R2 introducing a different carbonyl placement) can break infringement.

3) Is L a polyalkylene glycol linker, and is it PEG for claim 3?

Claim 1: L must be a polyalkylene glycol linker.
Claim 3: L must be polyethylene glycol.

A design-around often targets the linker: replacing PEG with a different oligomeric spacer, changing end-group chemistry, or altering the identity of the “linker” portion so it no longer matches the “polyalkylene glycol linker” definition.

4) Do the Core features match the X and Y attachment options?

Within Core:

X is restricted to bonds and a limited set of heteroatom-containing amide/amine/sulfonamide-like linkages.
Y is restricted to bond, optionally substituted C1-6 alkylene, optionally substituted phenyl, pyridinyl, polyethylene glycol linker, and —(CH2)1-6O(CH2)1-6—.

This blocks broader analogs with larger rings, different heterocycles outside “pyridinyl,” or different ether/linker spacers that do not fit the enumerated pattern.

How many patents likely cover this IBS scaffold, and what related estate should be searched?

You provided only the claims, not the patent bibliographic metadata (assignee, filing priority, specification examples) and not the full patent text needed to enumerate family members and citation clusters. With only the claim language available, the only accurate “landscape” statement is structural: the patent’s claim architecture typically correlates with a chemical series protected by:

Earlier priority patents covering the Core scaffold and NHE linkage concept.
Continuation/divisional family members narrowing to specific NHE embodiments, specific PEG-length ranges, or salt forms.
Method-of-use continuations claiming IBS treatment with the same compound set.
Formulation or dosing regimen patents that are often separate from the chemical claims, especially for oral delivery in IBS.

Because you did not supply patent number-to-family mapping sources, any attempt to list counts, family members, or competitor patents would require external data not included here. The enforceable scope of US 9,408,840 itself can still be analyzed with precision, but the broader “how many patents cover it” question cannot be answered reliably from the excerpt alone.

When does US 9,408,840 lose exclusivity, and what date drivers apply?

For a US utility patent, the key dates are governed by:

Patent term from earliest US non-provisional filing plus adjustments for patent term adjustment (PTA) and potential terminal disclaimers.
Patent term extension (PTE) is generally not applicable to most small-molecule methods of use unless the claimed invention is tied to an FDA-approved product under Hatch-Waxman PTE eligibility.

However, without filing date, priority date, PTA, and whether the patent is subject to any terminal disclaimer, there is no way to compute actual expiration dates from your excerpt.

What Orange Book status would matter for IBS generics, and how does this patent type affect it?

US 9,408,840 is a method-of-treatment patent for IBS with a defined compound structure. Orange Book listings typically include:

Drug product (NDC) entries
Approved active ingredient(s)
Listed patents: composition, method of use, and sometimes metabolites

This patent being a method claim means it can be listed as a “use” patent for a specific NDA/BLA product, creating Paragraph IV risk for generic applicants if the generic’s label would infringe the method claim.

But Orange Book status requires knowing:

which NDA/BLA the compound is tied to,
the listed patents for that product,
and the listed active ingredient naming.

No such product linkage is present in the provided information. A correct “Orange Book status” determination cannot be produced.

How could competitors design around claim 1’s structure constraints?

Design-around strategies inferred from the claim limitations:

1) Change n away from 2

If a candidate series uses different stoichiometry (n≠2), it falls outside the independent claim. This is often the most straightforward structural exit.

2) Alter R1/R2 while keeping the general scaffold

Because R1 and R2 are enumerated, candidates can try to introduce substituents not within the listed categories (while maintaining acceptable pharmacology). Examples of risky changes include:

R1 not being H or —SO2-NR7R8—
R2 not being H, —NR7(CO)R8, —SO2—NR7R8—, or —NR7R8
R7 not equal to hydrogen
R3 not equal to hydrogen

3) Replace L with a non-polyalkylene glycol linker or with a non-PEG linker

Claim 1 requires “polyalkylene glycol linker.” If L is replaced with a different class of linker (alkyl, aryl, cyclic spacer, non-PEG polymer), claim 1 breaks. Claim 3 breaks if L is not PEG.

4) Use a different Core linkage type (X) outside the enumerated set

Core’s X options are restricted. Changing the linkage chemistry outside the listed bond, —O—, —NH—, NHC(═O)—, NHC(═O)NH—, and —NHSO2— would avoid.

How to evaluate strength: claim breadth, likely validity posture, and enforcement leverage

Claim breadth (relative):

Claim 1 is moderately narrow due to the nested structural rules and the exact “n=2” constraint.
Dependent claims 2-6 reduce breadth further by selecting specific embodiments of NHE, PEG-only linker, specific Core members, specific compound selections, and specific salts.

Enforcement leverage:

If an accused drug’s molecule matches the listed NHE/PEG/Core embodiments, the patent can be asserted via claim 2/3/4 dependent pathways.
If infringement is argued only under claim 1’s generic variable definitions, litigation will hinge on chemical proof and claim construction of “polyalkylene glycol linker,” the meaning of “Core” graphical structure, and how the R-groups are interpreted for tautomeric or substituted states.

Validity posture:

Method claims tied to defined chemical structures often survive well because obviousness must overcome both the compound structure and the method treatment context.
But without specification and prosecution history, the exact validity risk from prior art cannot be quantified from your excerpt alone.

Claim-by-claim scope matrix for infringement planning (US 9,408,840)

Claim	Scope trigger	Break point for design-around
1	IBS treatment by administering compound with structure Core-L-(NHE)2 (n=2); NHE has R1/R2/R3/R7/R8 constraints; L is polyalkylene glycol; Core has restricted X and Y options	n≠2; NHE R-group constraints violated; L not polyalkylene glycol; Core X or Y outside enumerated set
2	Claim 1 plus NHE equals one of the enumerated NHE structures	NHE not matching the listed embodiments
3	Claim 1 plus L is polyethylene glycol linker	L not PEG
4	Claim 1 plus Core equals one of enumerated Core structures	Core not in the enumerated set
5	Claim 1 plus compound equals one of enumerated compounds	compound not in the enumerated set
6	Claim 1 plus salt equals one of enumerated pharmaceutically acceptable salts	salt not in enumerated set (or claim construction excludes it)

Key takeaways

US 9,408,840 is centered on a structure-defined IBS method claim requiring Core-L-(NHE)2 with n=2, NHE fixed R-group states, and L defined as a polyalkylene glycol linker (PEG-only in claim 3).
Infringement is most sensitive to four elements: n=2, NHE R-group rules (R3=H, R7=H, R8 links to L), L identity (polyalkylene glycol and PEG for dependent claims), and Core’s X/Y allowed linkages.
Dependent claims 2-6 likely map to specific embodiments in the specification and provide practical enforcement anchors when an accused product matches one enumerated NHE/Core/compound/salt form.
Freedom-to-operate risk for generics hinges on whether an accused or prospective candidate uses the same structural scaffold and whether an Orange Book method-of-use listing ties this patent to an approved IBS NDA/BLA label. Those product-linking facts are not included in the provided excerpt.

FAQs

1) What structural element in US 9,408,840 is most likely to be targeted for design-around?
The combination of L (polyalkylene glycol) and the exact n=2 NHE architecture, plus the restricted NHE R-group states, are the most direct design-around levers.

2) Does US 9,408,840 cover non-PEG polyalkylene glycol linkers?
Claim 1 covers polyalkylene glycol generally; claim 3 restricts to polyethylene glycol specifically.

3) Are method-of-use patents treated differently from composition patents for generic challenges?
They matter if the patent is listed for the approved product and the generic’s intended use or label would fall within the claimed method.

4) What happens if a compound has only one NHE group instead of two?
Claim 1 requires n=2, so a one-NHE analog would fall outside the independent claim.

5) Which dependent claims most directly narrow infringement beyond claim 1?
Claim 3 (PEG-only L), claim 4 (enumerated Core embodiments), and claim 2 (enumerated NHE embodiments) are typically the most narrowing.

References

US Patent 9,408,840 (claim set provided in prompt).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ardelyx Inc	IBSRELA	tenapanor hydrochloride	TABLET;ORAL	211801-001	Sep 12, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009334511	⤷ Start Trial
Brazil	PI0923861	⤷ Start Trial
Canada	2748607	⤷ Start Trial
China	102333759	⤷ Start Trial
China	103819403	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,408,840

Which drugs does patent 9,408,840 protect, and when does it expire?

Summary for Patent: 9,408,840